Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum

He, Yi; Jensen, Knud; Siebuhr, Anne Sofie; Karsdal, Morten; Larkin, J.; Bay‐Jensen, Anne‐Christine

doi:10.1016/j.ocarto.2021.100162

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this new test, it was shown that low levels of serum ARGS provided an odds ratio of 3 for the identification of fast radiographic progressors over 2 years in a cohort including 145 patients with knee OA. 120 The marker of tissue inflammation, serum CRPM, predicted the risk of OA progression independently of urinary CTX-II and serum COMP in 1335 participants of the Rotterdam study. 121 A panel of inflammatory markers have been evaluated in plasma in a 2-year prospective analysis of radiographic progression including 183 patients with SKOA.…”

Section: Markers Of Type II Collagenmentioning

confidence: 99%

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.

show abstract

Section: Markers Of Type II Collagenmentioning

confidence: 99%

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…One study investigated the sensitivity of sARGS to exercise and found minute increases in the hours following moderate exercise, very low day-to-day variation in the individual, but a substantial variation between individuals [ 29 ]. Two publications showing line graphs of individual variation of sARGS over hours and a few weeks found no significant diurnal or inter-day variation in sARGS on the same 20 subjects with knee OA that was not end-stage [ 11 , 12 ]. In a cohort of subjects with well-defined early-stage OA, we here present similar line graphs for both serum and synovial fluid following subjects over one year, and novel data on measures of long-term variability both within and between subjects in serum as well as in synovial fluid, in both early-stage OA and after ACL injury.…”

Section: Discussionmentioning

confidence: 99%

“…Such information is generally lacking for OA biomarkers. Only one prior study reported on measures of longitudinal and cross-sectional variability in markers of extracellular matrix metabolism [ 9 ], while some studies inform on diurnal variation or variation related to exercise [ [10] , [11] , [12] , [13] ].…”

Section: Introductionmentioning

confidence: 99%

“…For aggrecanase-generated ARGS several studies have reported on differences between patient groups [ 11 , [14] , [15] , [16] ], temporal changes after rupture of the anterior cruciate ligament (ACL) of the knee [ [17] , [18] , [19] , [20] ], and on diurnal variation in serum [ 11 , 12 ]. None of these studies have reported on measures of variability.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biological variation of human aggrecan ARGS neoepitope in synovial fluid and serum in early-stage knee osteoarthritis and after knee injury

Larsson¹,

Lohmander²,

Struglics³

2022

Osteoarthritis and Cartilage Open

View full text Add to dashboard Cite

Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis

Kalogera

Jansen

Bay‐Jensen

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

The association between structural changes and pain sensation in osteoarthritis (OA) remains unclear. Joint deterioration in OA leads to the release of protein fragments that can either systemically (serum) or locally (synovial fluid; SF) be targeted as biomarkers and describe structural changes and potentially pain. Biomarkers of collagen type I (C1M), type II (C2M), type III (C3M), type X (C10C), and aggrecan (ARGS) degradation were measured in the serum and SF of knee OA patients. Spearman’s rank correlation was used to assess the correlation of the biomarkers’ levels between serum and SF. Linear regression adjusted for confounders was used to evaluate the associations between the biomarkers’ levels and clinical outcomes. The serum C1M levels were negatively associated with subchondral bone density. The serum C2M levels were negatively associated with KL grade and positively associated with minimum joint space width (minJSW). The C10C levels in SF were negatively associated with minJSW and positively associated with KL grade and osteophyte area. Lastly, the serum C2M and C3M levels were negatively associated with pain outcomes. Most of the biomarkers seemed to mainly be associated with structural outcomes. The overall biomarkers of extracellular matrix (ECM) remodeling in serum and SF may provide different information and reflect different pathogenic processes.

show abstract

Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum

Cited by 3 publications

References 30 publications

Soluble biological markers in osteoarthritis

Soluble biological markers in osteoarthritis

Biological variation of human aggrecan ARGS neoepitope in synovial fluid and serum in early-stage knee osteoarthritis and after knee injury

Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis

Contact Info

Product

Resources

About